Skip to Main Content
Principal Investigator
Name
David Howard
Degrees
PhD
Institution
Emory University
Position Title
Associate Professor
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-127
Initial CDAS Request Approval
Mar 13, 2015
Title
Survival and comorbidities among persons eligible for lung cancer screening
Summary
Lung cancer screening recommendations and coverage policies rely heavily on results from the National Lung Screening Trial (NLST). We know little about how the screening-eligible US population in community practice settings differs in terms of demographics, socioeconomic status, comorbidity, or life expectancy from participants in the NLST research study.

The purpose of this study is to compare demographics, comorbidities, and survival between NLST participants and members of the screening-eligible population in the US. We measured the size and characteristics of the screening-eligible population (based on USPSTF and CMS criteria) using the Health and Retirement Study (HRS), an NIH-sponsored panel survey designed to collect information on the population of adults ages 50 and older.

We will consider an HRS respondent as eligible for lung cancer screening based on the USPSTF lung cancer screening recommendation if they 1) were between the ages of 55 and 80, 2) had at least 30 pack years of smoking history, and 3) currently smoked or quit within the past 15 years. We will classify respondents as eligible for lung cancer screening under fee-for-service Medicare if they meet the USPSTF criteria for smoking history and they also 1) self-reported that they were enrolled in Medicare Part B, 2) self-reported that they were not enrolled in a Medicare Advantage Plan, and 3) were between the ages of 55 and 77 years.
Aims

Aim 1: To compare the age distribution between NLST participants and screening-eligible adults.

Aim 2: To compare socioeconomic status (as measured by the receipt of a college degree) between NLST participants and screening-eligible adults.

Aim 3: To compare comorbidities (diabetes, cerebrovascular disease, heart disease) between NLST participants and screening-eligible adults.

Aim 4. To compare 5 year survival rates between NLST participants and screening-eligible adults.

Collaborators

Tom Richards, Division of Cancer Prevention and Control, CDC
Peter B. Bach, Memorial Sloan-Kettering Cancer Center

Related Publications